Introduction
============

Copy number variants (CNVs) are deletions or duplications of chromosomal segments ranging from a few thousand to several million base pairs. A number of population-based studies have shown that this type of genomic variant can affect as much as 12% of the human genome.^[@bib1]^ Many studies have gone on to demonstrate the importance of CNVs in determining human phenotypic variation and disease susceptibility.^[@bib2],\ [@bib3]^

The Autism Genome Project consortium (AGP) recently detected an excess of genes disrupted by rare CNVs in 996 individuals with autism spectrum disorder (ASD) in comparison to 1287 control subjects.^[@bib4]^ This increased burden demonstrates the relevance of CNVs in susceptibility to this early-onset neurodevelopmental condition. Unlike some other studies, where exceptionally rare homozygous CNVs were seen in long tracts of homozygosity-by-descent,^[@bib5]^ the AGP cohort contains very few consanguineous ASD pedigrees and therefore the vast majority of these rare CNVs are heterozygous.

Studies on both humans and mice have shown that CNVs can influence gene expression.^[@bib6],\ [@bib7]^ This has led many scientists to hypothesize that these heterozygous CNVs may influence susceptibility to neurodevelopmental disorders through a gene-dosage mechanism. For instance, it is easy to imagine how mild perturbations in axon guidance molecules could affect critical stages of brain development. Others have looked for evidence of an alternative mechanism whereby deletions might unmask recessive coding changes in the opposite allele.^[@bib8],\ [@bib9],\ [@bib10]^

A third possible mechanism exists for deletions or duplications with breakpoints disrupting two different genes. Where the two neighboring genes are encoded on the same chromosomal strand, such CNVs could potentially result in gene-fusion transcripts. A number of genomic rearrangements that lead to fusion transcripts have already been described in autism and schizophrenia.^[@bib11],\ [@bib12],\ [@bib13]^ If such transcripts are stable they may be translated into novel proteins with a possibility for deleterious gain-of-function effects.

Fusion-proteins have an important role in cancer genetics, most notably in leukemia, and can result from chromosomal translocation (eg *BCR-ABL* fusion gene on the Philadelphia chromosome). Somatic deletions of chromosome 21 have also been shown to result in *TMPRSS2*-*ERG* fusion transcripts in the majority of prostate cancers,^[@bib14]^ and the exact configuration of these transcripts appears to correlate with clinical outcome.^[@bib15]^ However, to our knowledge, there have been few systematic studies determining the frequency with which germline deletions and duplications can similarly lead to fusion genes/proteins ([Figure 1a and b](#fig1){ref-type="fig"}). Therefore, to address the question of how common CNV-induced fusion transcripts are and to assess whether this type of CNV may have a role in ASD susceptibility, we carried out a bioinformatic analysis of existing CNV calls based on published 1M SNP array data.^[@bib4]^ Validation of specific instances of such CNVs was then attempted using RT-PCR.

Materials and methods
=====================

CNV calls
---------

CNVs were called as part of a previous AGP study.^[@bib4]^ Briefly, DNA from individuals with ASD, parents and controls were genotyped using the Infinium 1M-single SNP microarray (Illumina, San Diego, CA, USA). High confidence CNVs were predicted by intersecting CNV calls from both iPattern and QuantiSNP algorithms (log Bayes Factor \>15). Previous analysis showed that validation rates were ∼95% for CNVs identified using this method.^[@bib4]^ From these data, rare CNV calls, present at \<1% of the combined sample, and greater than 30 kb in size were identified from a total of 996 cases and 1287 controls (all Caucasian). For CNVs of interest, raw SNP data was reviewed manually using BeadStudio version 3.0 (Illumina) ([Figure 1c](#fig1){ref-type="fig"}).

Bioinformatic analyses
----------------------

We used a bioinformatics approach to identify CNVs that show evidence of the breakpoints disrupting two different genes on the same strand. The following steps were applied: because of the relatively high density of SNPs compared to the size of the genes, the identified boundaries of the CNV were considered to be sufficiently exact. Those boundaries were tested against the location of RefSeq genes (NCBI build36/hg18) for overlap. Pairs of genes, transcribed in the same direction, and each containing an extremity of a CNV were flagged and counted. This selection also marked all intermediate genes in the same direction. The procedure was performed independently in the case and control groups. It was therefore possible to compare the number of times a group of genes was affected by a CNV between the two groups.

To determine whether the *MAPKAPK5-ACAD10* and *POLR1A-REEP1* duplications were ancestral, present on a single haplotype, genotype data for each trio was extracted from BeadStudio. Genotypes were phased for a total of 100 SNPs flanking the duplication (50 on either side or else until the shared haplotype finished). Haplotypes upon which the duplication was observed were then compared.

Quantitative PCR of CNV involving *SHANK3*
------------------------------------------

For family 3379, quantitative PCRs were performed in triplicate using the iQ SYBR Green Supermix (BioRad, Hercules, CA, USA), 0.2 *μ*ℳ of each primer and 20 ng of template DNA in a total reaction volume of 25 *μ*l. Thermocycling and data acquisition was carried out using the iQ5 iCycler (BioRad). Primers sets for *SHANK3* targeted intron 3, exon 10, exon 16 and intron 19 are as described.^[@bib16]^ A control amplicon in the *MAPK1* gene on chromosome 22q11.2 was also included.

Fine mapping the duplication involving *REEP1* and *POLR1A*
-----------------------------------------------------------

Long-range PCR was performed using primers 5′-GATATTGCTGCCCTTCTTGG-3′ and 5′-TGCAAAGAGCCAGCCTAGTT-3′ and the SequalPrep Long PCR kit (Invitrogen, Eugene, OR, USA) according to the manufacturer\'s suggested protocol. PCR products were purified using exonuclease I (NEB, Ipswich, MA, USA) and shrimp alkaline phosphatase (USB, Cleveland, OH, USA). Sanger sequencing of the junction fragment was then performed using BigDye chemistry (Applied Biosystems, Foster City, CA, USA). The forward PCR primer was sufficiently close to reach the breakpoint ([Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}).

Fine mapping the duplication involving *KIAA0319* and *TDP2*
------------------------------------------------------------

Long-range PCR was performed using primers 5′-ACGAGATGTGGCCAAAGTAG-3′ and 5′-ATTCTTGTTCTATTTGGCAGAC-3′ and the BIO-X-ACT long DNA polymerase kit (Bioline, London, UK) according to the manufacturer\'s suggested protocol. Sequencing was performed as described above, with each PCR primer and also an internal primer (5′-ACCTAATATTGAGTGTTTATGC-3′) that was required to reach the breakpoint ([Supplementary Figure 1b](#sup1){ref-type="supplementary-material"}).

RNA extraction and cDNA synthesis
---------------------------------

EBV-transformed peripheral lymphoblast cell lines (LCLs) were available for a subset of patients. Cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum (Invitrogen), ℒ-glutamine (final concentration 2 mℳ) and penicillin (500 U/ml) and streptomycin (5 *μ*g/ml). RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK) and cDNA was synthesized using the QuantiTect reverse transcriptase kit (Qiagen) according to the manufacturer\'s suggested protocol, using approximately 1 *μ*g of RNA as template.

RT-PCR and sequencing
---------------------

PCR primers were designed in exons closest to the CNV breakpoints, following manual inspection of log *R* ratios and allelic ratio data within BeadStudio. All CNVs tested were duplications; therefore the primers were designed as indicated ([Figure 1b](#fig1){ref-type="fig"}; [Supplementary Figure 1a-e](#sup1){ref-type="supplementary-material"}). For CNVs where the breakpoints were not clear, multiple primer combinations were tested. Primer sequences are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Thirty five cycles of PCR amplification were performed in a 20-*μ*l volume, with 0.5 *μ*l of cDNA as template, a final Mg^2+^ concentration of 1.5 mℳ, each primer at 200 nℳ and the BIOTAQ DNA polymerase (Bioline). The gene encoding beta-actin (*ACTB*) was used as a control. PCR products were visualized by UV illumination of 1.8% agarose gels stained with SYBR Safe (Invitrogen). Sequencing was performed as described above.

Expression analysis of the 5′ genes
-----------------------------------

To test whether the promoters of the genes comprising the 5′ end of the putative fusion transcripts were active in LCLs, cDNA was generated (detailed above). Primers were designed for the 5′ gene of the putative fusion product ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) and RT-PCR performed, with *ACTB* used as a positive control. PCRs were typically carried out using the PCR conditions described above. An annealing temperature of 55 °C was used in all instances except *ACTB* (56 °C). Expression was determined by the detection of a single band of the predicted size.

The various analysis strategies employed are also summarized in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}.

Results
=======

Genome-wide analysis of fusion CNV frequency
--------------------------------------------

In a previous study analyzing 996 individuals with ASD, a total of 2382 rare CNVs present in 889 individuals were observed.^[@bib4]^ Similarly, in 1287 control subjects, there were 3096 rare CNVs present in 1146 individuals. From these, we assessed which of these variants had the potential to lead to a fusion transcript. Intersecting CNVs with RefSeq gene coordinates indicated that 134/2382 (5.6%) and 200/3096 (6.5%) of rare CNVs could lead to fusion transcripts in cases and controls, respectively. Reported at the individual level, 122/996 ASD cases harbored at least one rare CNV of this type, compared with 179/1287 control subjects (*P*=0.89, Fisher\'s Exact Test). The frequencies distribution of putative fusion transcript forming CNV was not significantly different in cases compared with controls (*P*\>0.05; [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). The synapse is known to be of importance in ASD susceptibility. We therefore compared the frequency between cases and controls of putative fusion transcript forming CNVs involving at least one gene expressed in the human post-synaptic density.^[@bib17]^ However, no significant difference was observed (*P*\>0.05).

Despite the lack of a genome-wide increase in burden of potential fusion-gene generating CNVs in ASD, specific instances could still be of potential significance. Therefore, we further examined this class of CNV at single loci.

*REEP1-POLR1A* fusion gene
--------------------------

Initially, we decided to further examine individual putative fusion-gene generating CNVs based on differences in distribution between cases and controls. The CNV closest to reaching significance was a duplication on chromosome 2. This CNV was present in 3/996 cases (probands from families 13 131, 13 129, 14 284) and 0/1287 controls (*P*=0.08, Fisher\'s Exact Test). Analysis of SNP data indicated that the duplications were on the same haplotype (data not shown) and thus likely to represent an ancient ancestral event. Fine mapping experiments were carried out in family 14 284 that indicated the duplication was a direct tandem repeat involving chr2:86 136 225--86 364 443 ([Figure 2a](#fig2){ref-type="fig"}). This rearrangement thus fuses the 3′ end of *REEP1* with the 5′ end of *POLR1A*. Forward and reverse RT-PCR primers were designed in *REEP1* and *POLR1A* ([Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}) and tested using cDNA from family 14 284 (the one family for whom cDNA was available; in this family the father and proband carry the variant). However, all primer combinations tested failed to generate a PCR product.

Candidate gene approach
-----------------------

Next, we identified two CNVs as being of potential interest owing to the presence of genes strongly implicated in neurodevelopmental disorders. The first was a 96-kb putative *de novo* duplication of 22q13 in individual 3379.3 with predicted breakpoints in *SHANK3* and *RPL23AP82* ([Table 1](#tbl1){ref-type="table"}). *SHANK3* is a known ASD susceptibility gene.^[@bib16],\ [@bib18],\ [@bib19]^ However, closer examination of the SNP genotype data indicated that the CNV call was likely to be a false positive. This was confirmed by qPCR analysis of genomic DNA (data not shown).

The second CNV was an inherited duplication on 6p22.2 in Irish subject 13 083.973. This was predicted to fuse the first exon of *KIAA0319* with the 3′ end of the neighboring gene *TDP2*. *KIAA0319* is a dyslexia susceptibility gene^[@bib20],\ [@bib21],\ [@bib22]^ and there is known overlap of susceptibility CNVs between different neurodevelopmental disorders.^[@bib23],\ [@bib24]^ The resolution of the CNV in the 1M SNP data was sufficient to design long-range PCR primers and subsequent PCR confirmed the presence of the CNV as a tandem duplication in the proband and mother. PCR products were sequenced and the duplicated segment identified as chr6:24 728 714--24 766 602 ([Figure 2a](#fig2){ref-type="fig"}). Therefore, the CNV would fuse the first noncoding exon of *KIAA0319* with exons 4--7 of *TDP2*. It is unclear whether a viable open reading frame would result from a transcript with this combination of exons. EBV-transformed LCLs were obtained for both individuals carrying the CNV and used to generate cDNA. However, no fusion transcript was detectable by RT-PCR.

Identification of an expressed fusion transcript
------------------------------------------------

None of the previous three CNVs examined above generated a *bone fide* fusion transcript. However, to confirm that this class of CNV can generate fusion transcripts in our cohort, we screened another subset of putative fusion genes. The 134 rare CNVs with potential to cause fusion transcripts were filtered for those present in cases from the International Molecular Genetic Study of Autism Consortium (IMGSAC) cohort, for which we had direct access to LCLs. This identified 19 CNVs from 18 different families ([Table 1](#tbl1){ref-type="table"}). The 1M SNP genotyping results for these CNVs were assessed manually within BeadStudio. A number of these (including the putative duplication involving *SHANK3*) appeared to be likely false positive CNV calls due to noisy SNP data or gaps in coverage on the 1M array. Therefore, cell lines from four families harboring the three CNVs with the strongest evidence from the genotyping data were tested to identify fusion transcripts. Cell lines for probands were cultured, RNA extracted and used to generate cDNA. Primers were then designed to span between the two genes in the potential fusion transcript.

We were unable to detect transcripts for the CNVs fusing *SLC38A8-MBTPS1* or *DSG3-DSG4* from the probands of families 3199 and 3309, respectively. A PCR product was obtained for samples from families 3044 and 3075 showing that the ∼130-kb duplication on chromosome 12, joining the 5′ end of *MAPKAPK5* and the 3′ end of *ACAD10*, does lead to a *bone fide* fusion transcript ([Figure 2b](#fig2){ref-type="fig"}). Analysis of other family members confirmed that this CNV had been inherited by the probands\' affected sibling in both families, as well as one unaffected brother in family 3044 ([Figure 2c](#fig2){ref-type="fig"}). Sequencing of the PCR products showed the transcript runs from exon 7 of *MAPKAPK5* to exon 13 of *ACAD10*. The *ACAD10* portion of this novel transcript is out of frame and predicted to lead to 13 new amino acids followed by a stop codon ([Figure 2d](#fig2){ref-type="fig"}). Analysis of the SNPs flanking the duplication in all three IMGSAC families showed the duplication bearing haplotype to be identical, indicating the CNV was ancestral ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Overall this CNV was seen in 5/996 (0.5%) of cases and 5/1287 (0.4%) of controls.

Confirmation of gene expression in lymphoblasts
-----------------------------------------------

One potential explanation for the lack of observation of fusion transcripts was that the promoter of the 5′ gene is simply not active in LCLs. Therefore, we extracted RNA from control LCLs and subsequently generated cDNA. Transcripts were detected for *POLR1A*, *KIAA0319* and *DSG3*. However, we were unable to detect expression of *SLC38A8*. Thus, in the majority of cases examined, if a fusion transcript were generated, we would expect to observe it using the methods employed here.

Discussion
==========

In this study, we have assessed whether CNVs that lead to fusion transcripts may have a role in susceptibility to ASD. To do this we integrated CNV and RefSeq gene coordinates, looking for CNVs where the breakpoints intersect two different genes that are transcribed in the same direction. Our analysis indicates that there is no increased burden of this type of CNV in 996 cases compared with 1287 controls.

The sample size currently available gives our study limited power to detect association of CNVs at specific loci. For instance, in our analysis, the CNV closest to reaching significance involved the *REEP1* and *POLR1A* genes and reached *P*=0.08. *POLR1A* and *REEP1* encode polymerase (RNA) I polypeptide A and a mitochondrial receptor accessory protein, respectively. Interestingly, dominant mutations of *REEP1* lead to autosomal-dominant hereditary spastic paraplegia, and a recent study described a similar duplication involving exons 2--7 as part of the mutational spectrum of this gene.^[@bib25]^ It is possible that the loss of *POLR1A* 3′-regulatory elements in the fusion gene may lead to a loss of expression in LCLs, but that expression might still occur in other cell types. However, no other tissue types were available from the families to test this hypothesis. Therefore, this CNV may still potentially have a role in ASD susceptibility through our hypothesized mechanism.

Investigation of two candidate CNVs based on the previous identification of the genes involved in neurodevelopmental disorders indicated that neither were likely to be involved in ASD susceptibility through our hypothesized mechanism. The putative *de novo* duplication on chromosome 22q, involving *SHANK3* and *RPL23AP82*, was assessed by qPCR and shown to be a false positive. This finding illustrates one significant limitation of this study -- that although two separate CNV detection algorithms were used to improve the confidence of CNV calling,^[@bib4]^ upon closer examination, a proportion of the potentially fusion transcript forming CNV calls appeared to be imprecise in terms of breakpoints or else are false positives. Comparative studies have shown that there is still a surprising amount of variation between CNV calling algorithms, even when using the same raw data.^[@bib26]^ Further work to improve CNV calling algorithms would in turn improve accuracy of predicting CNVs that may lead to fusion transcripts. In contrast, the duplication involving *KIAA0319* (a susceptibility gene for dyslexia) was validated using genomic DNA, although no fusion transcript was identified.

In this study, a fusion transcript involving the *MAPKAPK5* and *ACAD10* genes was validated in two multiplex families. In both families tested, this chromosome 12 duplication and associated transcript were present in the probands\' affected sibling, as well as an unaffected brother in family 3044 ([Figure 2c](#fig2){ref-type="fig"}). However, sequencing indicated that the transcript had a premature stop codon and so may be degraded by nonsense-mediated decay. Within the whole AGP study, this variant was seen at a similar frequency in cases and controls. Thus, it is unlikely to have relevance to ASD susceptibility. It is interesting to note that *ALDH2* (encoding the aldehyde dehydrogenase 2 enzyme) is fully contained within this duplication. This gene is known to influence alcohol sensitivity^[@bib27]^ and risk for esophageal cancer,^[@bib28]^ and so it may be that this duplication confers some protection against these two conditions. The ancestral nature of this duplication suggests it is likely to be imputable in GWAS analysis, making this hypotheses easily testable.

One potential weakness in our attempts to confirm the presence or absence of fusion transcripts is the use of cDNA generated from LCLs, as opposed to cell types more directly related to ASD. However, work by Baron *et al*^[@bib29]^ has suggested that LCLs are suitable substitutes and several studies have used them to investigate ASD risk factors.^[@bib30],\ [@bib31]^

There are a number of reasons why 80% of the CNVs tested may not have resulted in detectable fusion transcripts. As discussed earlier, the gene making up the 5′ end of fusion product may not be expressed in LCLs. Our RT-PCR analyses appear to rule this possibility out for three of the CNVs (although it must be noted that large CNVs might alter chromatin structure). Second, it may be that the loss of 3′ control elements from the 5′ fused gene may alter expression, such that the fused product is not seen in LCLs. This may be the case with the *POLR1A*-*REEP1* and *KIAA0319*-*TDP2* CNVs. Third, it could be that fusion transcripts are expressed, but at levels below the sensitivity of the RT-PCR method used here. Fourth, the neighboring splice donor and acceptor sites may simply be incompatible and so may result either in unexpected cryptic transcripts (a possibility that could be addressed in future studies by the use of 3′-RACE or RNAseq) or else in a total absence of fusion transcript. Fifth, the resolution of CNV breakpoints may not have been sufficiently accurate to enable suitable primers to be designed. Finally, as all these CNVs happened to be duplications, we could not always be sure that the duplicated DNA was not present at a different genomic locus. The exception to the last two points are the *POLR1A-REEP1* and *KIAA0319-TDP* duplications, where fine-mapping confirmed the CNVs to be in a direct tandem orientation ([Figure 2a](#fig2){ref-type="fig"}).

In conclusion, our data do not lend support to the hypothesis that gain-of-function fusion genes are a common mechanism for ASD susceptibility. However, larger data sets are required to better assess individual loci. Our characterization of a *MAPAPK5-ACAD10* fusion transcript is consistent with other studies showing that rare germline CNVs can lead to fusion transcripts. Therefore, fusion genes and gain-of-function mechanisms should still be considered in future studies of genomic imbalance and disease susceptibility.

We gratefully acknowledge the families participating in the study, Dalila Pinto and members of the international Autism Genome Project consortium for sharing data, ideas and comments on the manuscript. Funding was from Autism Speaks and a Wellcome Trust core award 090532/Z/09/Z. ATP is currently supported by the NIHR Biomedical Research Centre. We gratefully acknowledge the resources provided by the Autism Genetic Resource Exchange (AGRE) Consortium and the participating AGRE families. The Autism Genetic Resource Exchange is a program of Autism Speaks and is supported, in part, by Grant 1U24MH081810 from the National Institute of Mental Health to Clara M Lajonchere (PI).

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![Detection of CNVs that may lead to fusion transcripts. (**a**) Schematic diagram showing two neighboring genes (blue and green) encoded on the same chromosomal strand. Black arrows show hypothetical position of exonic primers. Below, a deletion leads to a fusion gene whereby, upon transcription, the primers are close enough for efficient RT-PCR amplification to take place. (**b**) As above, but instead showing a tandem duplication. N.B. As well as the fusion gene, there is one functional copy of both genes on the mutated chromosome. (**c**) BeadStudio screenshot showing raw Log *R* Ratio and B allele frequency for a duplication on chromosome 12 in sample 3044.6. The duplication results in an increase to the Log *R* ratio and deviation in the allelic ratio for heterozygote variants away from the expected 0.5. Breakpoints disrupt different genes, encoded on the same chromosomal strand. SNPs within the duplication are highlighted in red. Region shown is chr12:110 600 000--110 900 000 (NCBI36/hg18).](ejhg201273f1){#fig1}

![Further characterization of CNVs of interest and validation of a fusion transcript. (**a**) Sequencing electropherogram showing genomic breakpoints for the *KIAA0319-TDP2* and *POLR1A-REEP1* duplications. (**b**) Results from RT-PCR analysis of RNA from four cell lines (two probands and two controls). The band at 243 bp indicates that the predicted fusion transcript is present. For each sample a positive and negative RT control was included (+ and − symbols, respectively). (**c**) Pedigrees showing the segregation pattern of the *MAPKAPK5-ACAD10* duplication in families 3044 and 3075. Presence of the fusion transcript duplication is highlighted in red. Arrows indicate the proband. (**d**) Sequencing electropherogram further validated the *MAPAPK5-ACAD10* fusion transcript, with predicted reading frame shown above.](ejhg201273f2){#fig2}

###### CNVs identified in probands from the IMGSAC cohort with potential to result in a fusion transcript

  *Chr*    *Start*           *End*             *Size*           *Gene 1*         *Gene 2*       *Family ID*    *Type*
  -------- ----------------- ----------------- ------------- -------------- ------------------- ------------- ---------
  2        32 483 938        33 184 723        700 785          *BIRC6*           *LTBP1*       3022             Dup
  2        110 206 673       110 615 080       408 407           *MALL*      *LIMS3-LOC440895*  3181             Del
  2        110 206 673       110 615 080       408 407           *MALL*      *LIMS3-LOC440895*  3266             Del
  2        110 206 673       110 615 080       408 407           *MALL*      *LIMS3-LOC440895*  3049             Del
  2        170 311 824       170 375 059       63 235           *KLHL23*           *SSB*        3423             Del
  4        1 711 332         1 779 448         68 116           *TACC3*           *FGFR3*       3228             Dup
  5        37 274 997        37 349 755        74 758           *NUP155*         *C5orf42*      3267             Dup
  5        70 274 080        70 451 560        177 480           *SMN1*           *SMN2*        3020             Dup
  6        167 143 252       167 264 573       121 321         *RNASET2*         *RPS6KA2*      3303             Dup
  9        138 488 774       139 538 498       1 049 724        *PNPLA7*         *SEC16A*       3228             Dup
  **12**   **110 665 461**   **110 799 555**   **134 094**    ***ACAD10***    ***MAPKAPK5***    **3044**       **Dup**
  12       110 665 461       110 799 555       134 094          *ACAD10*        *MAPKAPK5*      3436             Dup
  **12**   **110 666 628**   **110 799 555**   **132 927**    ***ACAD10***    ***MAPKAPK5***    **3075**       **Dup**
  **16**   **82 604 216**    **82 684 284**    **80 068**     ***MBTPS1***     ***SLC38A8***    **3199**       **Dup**
  17       30 708 148        30 792 312        84 164           *SLFN13*         *SLFN11*       3431             Del
  **18**   **27 222 369**    **27 305 675**    **83 306**      ***DSG3***       ***DSG4***      **3309**       **Dup**
  19       46 041 879        46 073 380        31 501           *CYP2A7*         *CYP2A6*       3304             Dup
  19       46 041 879        46 073 380        31 501           *CYP2A7*         *CYP2A6*       3435             Del
  22       49 486 044        49 582 267        96 223         *RPL23AP82*        *SHANK3*       3379             Dup

For those in bold, we attempted to experimentally validate the presence of a fusion transcript.
